NAD+ injection safety
What are the side effects of NAD+ injections?
NAD+ injection side effects are not reliably quantified for the at-home compounded products sold online. FDA has reported severe chills, shaking, vomiting and fatigue after injectable NAD+ products prepared with unsuitable ingredients, with symptoms consistent with excessive endotoxins. That warning concerns product quality and does not mean every NAD+ injection causes those reactions. A small IV pilot focused on short-term metabolites and was not designed to define the full side-effect rate of today's subcutaneous subscriptions.
Separates product-quality reactions reported by FDA from route-specific study evidence and avoids presenting a seller's mild-symptom list as a complete safety profile. It is a bounded source review, not a systematic review or individual medical advice.
FDA reports
Severe chills, shaking, vomiting and fatigue in specific injectable cases
Evidence limit
Small IV pilot, not current home-injection subscriptions
Quality issue
Compounded drugs are not reviewed by FDA before marketing
Which NAD+ injection reactions has FDA reported?
FDA reported severe chills, shaking, vomiting and fatigue after injectable NAD+ drugs prepared with food-grade ingredients unsuitable for sterile compounding. The agency said the symptoms were consistent with excessive endotoxins.
Those reports identify a specific compounding concern. They do not provide a general incidence rate for every NAD+ injection or identify the providers in Longevity Ranked's table as the source of those cases.
What does the human NAD+ IV study tell us about side effects?
The 2019 pilot involved eleven men, eight receiving a six-hour IV infusion and three receiving saline. Its main purpose was to measure metabolism over a short period, not establish the safety profile of subcutaneous home injections.
Its small sample, route and study design sharply limit any claim about how often current injection customers experience side effects.
Why does compounding change the safety question?
FDA does not approve compounded drugs or review them before marketing for safety, effectiveness and quality. Contamination, incorrect strength or unsuitable ingredients can create risks beyond the expected effect of NAD+ itself.
A 2026 FDA recall also covered specific compounded injectable products, including NAD+, after out-of-specification results. A recall of named lots is not evidence that all compounded NAD+ is defective.
What should I ask an online NAD+ provider?
Ask which pharmacy will dispense the prescription, the exact concentration and quantity, whether the product is intended for sterile injection, what adverse symptoms require urgent care and how a suspected reaction is reported.
Use the actual prescriber and pharmacy for individual advice. This page does not diagnose a reaction, recommend a dose or tell a reader to continue or stop a prescription.
Where can I compare current NAD+ providers?
The pages below compare public product and contract information. Some are labeled partner links. Any commission we receive does not change evidence claims or table order.
Partner link; we may earn a commission. Editorial order and findings do not change.
Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate.
Sprout Health’s NAD+ injection referral offer excludes California.
Which sources support this answer?
Sources were checked September 21, 2026. They define the product, population and evidence limits used above; they do not determine individual suitability.
These are products marketed in the longevity category, not established lifespan-extension treatments. Compounded drugs are not FDA-approved. This publication compares public information; a clinician must assess individual suitability. How we compare.